]>
IRCT20200410047009N1 IRCT 2020-04-26 Iran University of Medical Sciences The effect of Naproxen in recovery and reducing mortality in patients with COVID-19 Evaluation of the role of naproxen as adjunctive therapy with standard therapies and its efficacy in the early improvement and reduced mortality rate of COVID-19 patients 2020-04-13 anticipated 101 Complete https://irct.ir/trial/47052 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two equal groups of intervention and control by simple randomization and ABAB quadruple blocking method. 4 covid-19 disease. Intervention 1: Intervention group: A group of COVID-19 patients who will receive 500 mg Naproxen tablets 3 times a day for 10 days orally, in addition to the standard treatment provided in the latest national guide which the control group receives. Intervention 2: Control group: A group of patients will be treated according to the standard treatment provided in the latest national COVID-19 guide:Two-drug regimen: Oseltamivirwith hydroxychloroquine / chloroquine- Three-Phase Diet: Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / RitonavirFour-Phase Diet:Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / Ritonavir and Ribavirin. Yes - There is a plan to make this available What will be shared: Information on the results of the use of naproxen When: The first access, 6 months after publishing the results To whom: For researchers working in academic institutions Conditions: Physicians are allowed to use data to treat patients. Where to obtain: Maryam Esghaei How to obtain: Receive the documents by sending an e-mail to Dr Maryam Esghaei. Comments:
public Maryam Esghaei
Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran,
Tehran Iran (Islamic Republic of) 14665354 +98 21 8670 3014 esghaei.m@iums.ac.ir Iran University of Medical Sciences scientific Maryam Esghaei
ran University of Medical Sciences, Shahid Hemmat Highway, Tehran
Tehran Iran (Islamic Republic of) تهران، بزرگراه همت ج +98 21 8670 3014 esghaei.m@iums.ac.ir Iran University of Medical Sciences Iran (Islamic Republic of) Patients whose SARS-CoV-2 infection has been confirmed using PCR Age over 18 years The conscious consent form must be completed and signed by the patient or his companion The patient should participate in the research voluntarily 18 years no limit Both High creatinine and kidney problems In gastrointestinal ulcers Other conditions of contraindications to the use of Naproxen U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: A group of COVID-19 patients who will receive 500 mg Naproxen tablets 3 times a day for 10 days orally, in addition to the standard treatment provided in the latest national guide which the control group receives. Control group: A group of patients will be treated according to the standard treatment provided in the latest national COVID-19 guide:Two-drug regimen: Oseltamivirwith hydroxychloroquine / chloroquine- Three-Phase Diet: Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / RitonavirFour-Phase Diet:Oseltamivir with Hydroxychloroquine / Chloroquine and Lopinavir / Ritonavir and Ribavirin Recovery in COVID-19 patients. Timepoint: At the beginning (day zero) and the end of the treatment period (day 10). Method of measurement: Examination of clinical signs. Mortality rate in COVID-19 patients. Timepoint: At the end of treatment period. Method of measurement: The percentage of mortality rate in the study population. Iran University of Medical Sciences Approved 2020-03-18 Ethics committee of Iran University of Medical Sciences Iran University of Medical Sciences, Shahid Hemmat Highway, Tehran Tehran Tehran Iran (Islamic Republic of)